Skip to content

Genetics of Mendelian Diseases in Qatar

Genetics of Mendelian Diseases in Qatar

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02021734
Enrollment
400
Registered
2013-12-27
Start date
2012-11-19
Completion date
2025-02-28
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mendelian Disorders

Brief summary

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools.

Detailed description

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. These include high-throughput sequencing and genotyping along with the necessary bioinformatics analyses that will lead to the discovery of the causes of most inherited diseases in the region.The secondary objective will be to build a comprehensive catalogue of genetic variation in the Arab world. This will include all detected mutations, not only the subset that are causing disease (from primary objective), but also known trait-altering mutations as well as general diversity on the DNA level among human populations of this region. This catalogue can become a widely useful resource for many projects down the road, as it relies on anonymizing individual samples and instead displaying data in aggregate as the cohorts of collected samples grow over the years. The study will include all genetic disorders from all ethnic backgrounds but Mendelian disease for which a gene mutation has already been identified will be excluded. Evidence of Mendelian Transmission determined by fulfilling one of the following criteria: Multiple affected family members (at least first degree relative with disease) History of consanguinity Severe disease in newborn in the absence of family history Sydromic disease in single individuals Congenital abnormality affecting major organ system(s) Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)

Interventions

None listed

Sponsors

Hamad Medical Corporation
CollaboratorINDUSTRY
Weill Cornell Medical College in Qatar
CollaboratorOTHER
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All included individuals must provide informed consent * All genetic disorders are included * All ethnic backgrounds are accepted * Disease must be genetic with no evident environmental cause * Evidence of Mendelian Transmission determined by fulfilling one of the following criteria: * Multiple affected family members (at least first degree relative with disease) * History of consanguinity * Severe disease in newborn in the absence of family history * Sydromic disease in single individuals * Congenital abnormality affecting major organ system(s) * Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)

Exclusion criteria

* Individuals who do no consent to be included * Mendelian disease for which a gene mutation has already been identified * Individuals for which a molecular diagnosis has already been established by alternative method * Disease for which an environmental factor is most likely the cause * Disease for which late age of onset rule out Mendelian transmission * Common diseases for which late age of onset rule out Mendelian transmission

Design outcomes

Primary

MeasureTime frameDescription
Next generation sequencing1 hourUse next generation sequencing to detect novel disease causing mutations

Countries

Qatar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026